JACC: HEART FAILURE VOL.8,NO.4,2020
PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF
CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE
CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/).
FEATURED STATE-OF-THE-ART REVIEW
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF
John R. Teerlink, MD,a Rafael Diaz, MD,b G. Michael Felker, MD, MHS,c John J.V. McMurray, MD,d Marco Metra, MD,e f g g h g Scott D. Solomon, MD, Jason C. Legg, PHD, Gustavo Büchele, MD, Claire Varin, MD, Christopher E. Kurtz, MD, i g Fady I. Malik, MD, PHD, Narimon Honarpour, MD, PHD
HIGHLIGHTS Decreased systolic function is a central factor in HFrEF.